SEHK:3933Pharmaceuticals
The Bull Case For United Laboratories International Holdings (SEHK:3933) Could Change Following Key Cefoperazone-Sulbactam Approval
United Laboratories International Holdings recently reported that its wholly owned Zhongshan branch of Zhuhai United Laboratories received China National Medical Products Administration approval, with quality and efficacy consistency evaluation, for its 2.0g Cefoperazone Sodium and Sulbactam Sodium for Injection, already classified as a Category B drug in the 2024 National Medical Insurance Drug List.
This outcome strengthens the company’s anti-infective portfolio by validating a...